Cite

    Pui, C. et al. (n.d.). Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet oncology. 16 (4), pp. 465-474. [Online].